Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main inclusion criteria:~- Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald's criteria.~Main exclusion criteria:~- Patient suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm A (Type: EXPERIMENTAL): Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
- Experimental Arm B (Type: EXPERIMENTAL): Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
- Placebo Comparator A (Type: PLACEBO_COMPARATOR): Participants receive placebo given orally twice daily.
- Placebo Comparator B (Type: PLACEBO_COMPARATOR): Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).